THE ROLE OF ERYTHROPOIETIN IN TREATMENT OF ANEMIA IN CANCER PATIENTS
https://doi.org/10.17709/2409-2231-2017-4-2-5
Abstract
Malignant neoplasms are a serious pathological condition, both in terms of the course of the disease and the need for treatment, and a prognosis for the life of patients. The deterioration in the quality of life, social disadaptation (reduced physical activity, job change, fatigue, etc.) is a complication of the course of the disease caused by the development of anemia, which requires a vital need for its correction. This article analyzes the efficacy of recombinant erythropoietin — Epoetin-theta in the treatment of patients with NON — myeloid tumors and CRF (chronic renal failure) in cancer patients. The high efficacy and safety of drug therapy in this category of patients are demonstrated. Recommendations are given on the optimal dose of the drug in order to obtain the most pronounced clinical effect of treatment, increasing the therapeutic dose of the drug with an insufficient increase in the hemoglobin level by 100% or more allows an individual approach to the correction of anemia. The possibility of its application in routine clinical practice of the oncologist’s doctor, namely in out-patientpolyclinic conditions, has been determined.
About the Authors
P. G. Berezin
Tambov Regional Oncology Clinical Dispensary
Russian Federation
Russian Federation
Petr G. Berezin, oncourologist, Head of Consultative-Polyclinic Department
For correspondence: Address: 29V Moskovskaya St., Tambov, 392000
V. V. Milovanov
Tambov Regional Oncology Clinical Dispensary
Russian Federation
Vladimir V. Milovanov, Chief Physician
Russian Federation
Vladimir V. Milovanov, Chief Physician
A. A. Ivannikov
Tambov Regional Oncology Clinical Dispensary
Russian Federation
Andrey A. Ivannikov, Deputy chief doctor on medical division
Russian Federation
Andrey A. Ivannikov, Deputy chief doctor on medical division
References
1. Krantz SB. Erythropoietin. Blood. 1991; 77 (3): 419–434.
2. Nowrousian MR, et al. Pathophysiology of Cancer-related anemia. In Smythe J. et al. (eds). Rh-erythropoietin in Cancer Supportive Treatment. New-York: Marcel Dekker, 1966, p.13–34.
3. .Means RT Jr. Pathogenesis of the anemia of chronic disease: a cytokine — mediated anemia. Cytokines Cell Mol Ther. 1995; 13 (3): 32–37.
4. Salvarani C, Casali B, Salvo D, Brunati C, Macchioni PL, Massai G, et al. The role of interleuk ine-1 erythropoietin and red cell bound im m unoglobulins in the anem ia of rheumatoid arthritis. CEIN Exprheumatol. 2000; 9: 241–246 .
5. Canaparo R, Casale F, Muntoni E, Zara GP, Della Pepa C, Berno E, et al. Plasma erythropoietin concentrations in patients receiving intensive platinum or nonplatinum chemotherapy. Br J ClinPharmacol. 2000; 50 (2): 146–153 .
6. Pivot X, Guardiola E, Etienne M, Thyss A, Foa C, Otto J, et al. An analysis of potential factors allowing an individual prediction of cisplatin-induced anemia. Eur J Cancer 2000; 36 (7): 852–85. DOI: 10.1016/S0959–8049(00)00010–17.
7. Wood PA, Hrushesky WJ. Cisplatin — associated anemia: An erythropoietin deficiency syndrome. J Clin Invest. 1995; 95 (4): 1650–1659. DOI: 10.1172/JCI117840
8. Coiffiet B. Anemia associated with non- platinum chemotherapy (CT) for Hodgkins lymphoma (NHL). Eur J Cancer. 1999; 35 (Suppl 4): S331 (abstr).
9. Groopman JE, Itri LM. Chemotherapy-induced anemia in adults: incidenceand treatment. J Nate Cancer Inst. 1999; 91 (19): 1616–1634.
10. Macdougall IC. Novel erythropoiesis-stimulating agents: a new era in anemia management. Clin J Am Soc Nephrol. 2008 Jan; 3 (1): 200–2007. DOI: 10.2215/CJN.03840907
11. Babicheva LG, Poddubnaya IV. Lechenie anemii v onkologii: rol’ novogo stimulyatora eritropoeza Aranesp (darbepoetin al’fa). Journal of Modern Oncology. 2007; 9 (3): 69–74.(In Russian).
12. Beer TM, Tangen CM, Bland LB, Thompson IM, Crawford ED. Prognostic value of anemia in newly diagnosed metastatic prostate cancer: a multivariate analysis of southwest oncology group study 8894.J Urol. 2004 Dec;172 (6 Pt 1):2213–7.
13. Ludwig H, Birgegard G, Barret-Lee P, et al. Prevalence and management of anemia in patients with hematologic maligmancies and solid tumors: results from the European Cancer anemia Survey (ECAS). Blood 2002 abstr 884.
14. Skillings JR, Rogers-Melamed I, Nabholtz JM, Sawka C, Gwadry-Sridhar F, Moquin JP, et al. An epidemiological review of red cell transfusions in Cancer chemotherapy. Cancer Prev Control. 1999 Jun; 3 (3): 207–212 .
15. Barrett-Lee PJ, Bailey NP, O’Brien ME, Wager E. Large-scale UK audit of blood transfusion reguirements and anemia in patients receiving cytotoxic chemotherapy. Br J Cancer. 2000 Jan; 82 (1): 93–97. DOI: 10.1054/bjoc.1999.0883
16. .Mohammed A, Bagalagel A, MacDonald K, Abraham I. Clinical efficacy and safety of XM01, a biosimilar recombinant human erythropoietin, in the management of anemia. Biosimilars. 2013; 3: 45–53. DOI: 10.2147/BS.S28709
17. Tjulandin SA, Bias P, Elsässer R, Gertz B, Kohler E, Buchner A. Epoetin Theta with a New Dosing Schedule in Anaemic Cancer Patients Receiving Nonplatinum-Based Chemotherapy: A Randomised Controlled Trial. Arch Drug Inf. 2011 Sep; 4 (3): 33–41. DOI: 10.1111/j.1753–5174.2011.00035.x
Review
For citations:
Berezin P.G., Milovanov V.V., Ivannikov A.A. THE ROLE OF ERYTHROPOIETIN IN TREATMENT OF ANEMIA IN CANCER PATIENTS. Research and Practical Medicine Journal. 2017;4(2):37-42. (In Russ.) https://doi.org/10.17709/2409-2231-2017-4-2-5
Views:
1721
Email this article 